Clinical Trials | March 23, 2023
Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Various healthcare companies are already implementing high-tech solutions into existing healthcare systems.
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Mindset disagrees with and denies the allegations set forth from Reunion.
A funding to expand operations and provide better patient care
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
Time to combine innovation, access and technology to deliver positive patient outcomes
Subscribe To Our Newsletter & Stay Updated
